Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study


Disclosures: Conflict of interest: U.P. has received research support from TEVA. C.Th. is part owner of AgenDix GmbH. All other authors declare no competing conflict of interest. S.K. gratefully acknowledges to be supported by the Olympia-Morata fellowship program from the Medical Faculty of the Heidelberg University as well as financial support by Deutsche Forschungsgemeinschaft within the funding programme Open Access Publishing, by the Baden-Württemberg Ministry of Science, Research and the Arts and by Ruprecht-Karls-Universität Heidelberg. M.J.L. is supported by a grant from the NCI (NCI Leukemia SPORE P50 CA100632). R.B.W. is a Leukemia & Lymphoma Society Scholar in Clinical Research. Z.R., J.M., P.Z. and T.S. were supported by the Ministry of the Czech Republic, grant No. 15-25809A. Data from the AML10, AML11, AML12, AML14, AML15, AML16, and AML17 trials were supplied by Cardiff University HCTU on behalf of the NCRI AMLWG.

Contributions: S.K. and R.F.S. were responsible for the concept of this paper, contributed to the literature search data collection, analyzed and interpreted data, and wrote the manuscript. M.J.L. was responsible for the concept of this paper, contributed to the literature search data collection, contributed patients, analyzed and interpreted data, and critically revised the manuscript. D.G. performed research. C.T. and C.Th. performed research and critically revised the manuscript. R.K.H., M.R.L., A.M.B., J.W., K.M., C.S., M.R.B., M.A.E., A.E.P., Z.R., J.M., P.Z., T.S., S de B., K.M., R.B.W., A.K., A.K.B., A.D.H., U.P., G.E., R.M.S., C.R., M.S.T., E.H.E., C.M.T., and N.H.R. contributed patients and critically revised the manuscript. All authors reviewed and approved the final manuscript.